Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view
Introduction: Sacubitril/valsartan reduces cardiovascular morbidity and mortality in patients with systolic dysfunction (SD). The aim of the present study was to assess the evolution of chronic kidney disease (CKD) patients after initiating sacubitril/valsartan. Methods: We included 66 consecutive C...
Main Authors: | Borja Quiroga, Antonio de Santos, David Sapiencia, Yamila Saharaui, Vicente Álvarez-chiva |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-11-01
|
Series: | Nefrología (English Edition) |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2013251419301658 |
Similar Items
-
Experiencia clínica con sacubitrilo/valsartán en pacientes con insuficiencia renal: la visión del nefrólogo
by: Borja Quiroga, et al.
Published: (2019-11-01) -
Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01) -
Sacubitril/valsartan: A practical guide
by: Cândida Fonseca, et al.
Published: (2019-05-01) -
Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience
by: Sara C. Pereira, et al.
Published: (2023-02-01) -
Cystic Kidney Diseases From the Adult Nephrologist’s Point of View
by: Roman-Ulrich Müller, et al.
Published: (2018-03-01)